Relation between C-Reactive protein and impaired fasting glucose in obese subjects

Inflammation

Volumn 35, Issue 5, 2012, Pages 1742-1746

  Simental Mendía, Luis E ^a   Lazalde, Brissia ^a,b   Zambrano Galván, Graciela ^b   Simental Saucedo, Luis ^a   Rábago Sánchez, Elizabeth ^b   Rodríguez Morán, Martha ^a   Guerrero Romero, Fernando ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSIDAD JUÁREZ DEL ESTADO DE DURANGO   (Mexico)

Author keywords

C reactive protein; Impaired fasting glucose; Inflammation; Obesity; Type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; HIGH SENSITIVITY C REACTIVE PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISORDERS OF CARBOHYDRATE METABOLISM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED FASTING GLUCOSE; MAJOR CLINICAL STUDY; MALE; OBESITY;

ADULT; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FASTING; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; INTERLEUKIN-6; MALE; OBESITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84866742730     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-012-9492-z     Document Type: Article

References (35)

1. Ford, E.S. 2005. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 28(11): 2745-2749.
2. Hajer, G.R., T.W. van Haeften, and F.L. Visseren. 2008. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. European Heart Journal 29(24): 2959-2971.
3. Hansen, D., P. Dendale, M. Beelen, R.A. Jonkers, A. Mullens, L. Corluy, et al. 2010. Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 diabetes patients. European Journal of Applied Physiology 109 (3): 397-404.
4. Browning, L.M., J.D. Krebs, E.C. Magee, G. Frühbeck, and S.A. Jebb. 2008. Circulating markers of inflammation and their link to indices of adiposity. Obesity Facts 1(5): 259-265.
5. Pickup, J.C., and M.A. Crook. 1998. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41(10): 1241-1248.
6. Pickup, J.C. 2004. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27(3): 813-823.
7. Pearson, T., G. Mensah, W. Alexander, J.L. Anderson, R.O. Cannon 3rd, M. Criqui, et al. 2003. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107(3): 499-551.
8. Lagrand, W.K., C.A. Visser, W.T. Hermens, H.W. Niessen, F.W. Verheugt, G.J. Wolbink, et al. 1999. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon? Circulation 100(1): 96-102.
9. Yudkin, J.S., C.D.A. Stehouwer, J.J. Emeis, and S.W. Coppack. 1999. C-reactive protein in healthy subjects: Association with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from the adipose tissue? Arteriosclerosis, Thrombosis, and Vascular Biology 19(4): 972-978.
10. Festa, A., R. D'Agostino, G. Howard, L. Mykkänen, R.P. Tracey, and S.M. Haffner. 2000. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102(1): 42-47.
11. Sakkinen, P.A., P. Wahl, M. Cushman, M.R. Lewis, and R.P. Tracey. 2000. Clustering of procoagulation, inflammation and fibrinolysis variables with metabolic factors in insulin resistance syndrome. American Journal of Epidemiology 152(10): 897-907.
12. Hak, E.A., H.A. Pols, C.D.A. Stehouwer, J. Meijer, A.J. Kiliaan, A. Hofman, et al. 2001. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: The Rotterdam Study. Journal of Clinical Endocrinology and Metabolism 86(9): 4398-4405.
13. Temelkova-Kurktschiev, T., G. Siegert, S. Bergmann, E. Henkel, C. Koehler, W. Jaross, et al. 2002. Subclinical inflammation is strongly related to insulin resistance but not insulin secretion in a high risk population for diabetes. Metabolism 51(6): 743-749.
14. Müller, S., S. Martin, W. Koenig, P. Hanifi-Moghaddam, W. Rathmann, B. Haastert, et al. 2002. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 45(6): 805-812.
15. Temelkova-Kurktschiev, T., E. Henkel, C. Koehler, K. Karrei, and M. Hanefield. 2002. Subclinical inflammation in newly detected type II diabetes and impaired glucose tolerance. Diabetologia 45 (1): 151.
16. Nichols, G.A., T.A. Hillier, and J.B. Brown. 2007. Progression from newly acquired impaired fasting glucose to type 2 diabetes. Diabetes Care 30(2): 228-233.
17. Santaguida, P.L., C. Balion, D. Hunt, K. Morrison, H. Gerstein, P. Raina, et al. 2005. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evidence Report/ Technology Assessment (Summary) 128: 1-11.
18. Guerrero-Romero, F., M. Rodríguez-Morán, R. Pérez-Fuentes, M.C. Sánchez-Guillén, M. González-Ortiz, E. Martínez-Abundis, et al. 2008. Prediabetes and its relationship with obesity in Mexican adults: The Mexican Diabetes Prevention (MexDiab) Study. Metabolic Syndrome and Related Disorders 6(1): 15-23.
19. Guerrero-Romero, F., and M. Rodríguez-Morán. 2002. Relationship between serum magnesium levels and C-reactive protein concentration, in non-diabetic, non-hypertensive obese subjects. International Journal of Obesity and Related Metabolic Disorders 26(4): 469-474.
20. Gupta, A.K., and W.D. Johnson. 2010. Prediabetes and prehypertension in disease free obese adults correlate with an exacerbated systemic proinflammatory milieu. Journal of Inflammation (Lond) 7: 36.
21. Doi, Y., Y. Kiyohara, M. Kubo, Y. Tanizaki, K. Okubo, T. Ninomiya, et al. 2005. Relationship between C-reactive protein and glucose levels in community-dwelling subjects without diabetes: The Hisayama Study. Diabetes Care 28(5): 1211-1213.
22. Lin, J., M. Zhang, F. Song, J. Qin, R. Wang, P. Yao, et al. 2009. Association between C-reactive protein and pre-diabetic status in a Chinese Han clinical population. Diabetes/Metabolism Research and Reviews 25(3): 219-223.
23. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. 2003. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26(11): 3160-3167.
24. Ridker, P.M. 2003. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107 (3): 363-369.
25. Guerrero-Romero, F., L.E. Simental-Mendía, M. González- Ortiz, E. Martínez-Abundis, M.G. Ramos-Zavala, E. Martínez- Abundis, et al. 2010. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemichyperinsulinemic clamp. Journal of Clinical Endocrinology and Metabolism 95(7): 3347-3351.
26. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 2003. Hypertension 42(6):1206-1252.
27. Dehghan, A., I. Kardys, M.P. de Maat, A.G. Uitterlinden, E.J. Sijbrands, A.H. Bootsma, et al. 2007. Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 56(3): 872-878.
28. Hu, F.B., J.B. Meigs, T.Y. Li, N. Rifai, and J.E. Manson. 2004. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53(3): 693-700.
29. Han, T.S., N. Sattar, K. Williams, C. Gonzalez-Villalpando, M.E. Lean, and S.M. Haffner. 2002. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25 (11): 2016-2021.
30. Nakanishi, S., K. Yamane, N. Kamei, M. Okubo, and N. Kohno. 2003. Elevated C-reactive protein is a risk factor for the development of type diabetes in Japanese Americans. Diabetes Care 26(10): 2754-2757.
31. Scherer, P.E., S. Williams, M. Fogliano, G. Baldini, and H.F. Lodish. 1995. A novel serum protein similar to C1q, produced exclusively in adipocytes. Journal of Biological Chemistry 270 (45): 26746-26749.
32. Winkler, G., S. Kiss, L. Keszthelyi, Z. Sápi, I. Ory, F. Salamon, et al. 2003. Expression of tumor necrosis factor (TNF)-alpha protein in the subcutaneous and visceral adipose tissue in correlation with adipocyte cell volume, serum TNF-alpha, soluble serum TNFreceptor-2 concentrations and C-peptide level. European Journal of Endocrinology 149(2): 129-135.
33. Chu, N.F., D. Spiegelman, G.S. Hotamisligil, N. Rifai, M. Stampfer, and E.B. Rimm. 2001. Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis 157(2): 495-503.
34. Mathieu, P., P. Poirier, P. Pibarot, I. Lemieux, and J.P. Després. 2009. Visceral obesity: The link among inflammation, hypertension, and cardiovascular disease. Hypertension 53(4): 577-584.
35. Gastaldelli A, Folli F, DeFronzo RA. The product of triglycerides and glucose as index of insulin resistance. Validation in the SAM study. Journal of Clinical Endocrinology of Metabolism EPUB 28 July 2010.